dc.creatorMartínez-Aguayo, Juan Carlos
dc.creatorSilva, Hernán
dc.creatorArancibia, Marcelo
dc.creatorAngulo, Claudia
dc.creatorMadrid, Eva
dc.date.accessioned2019-03-18T11:54:58Z
dc.date.available2019-03-18T11:54:58Z
dc.date.created2019-03-18T11:54:58Z
dc.date.issued2016
dc.identifierRevista Chilena de Neuro-Psiquiatria, Volumen 54, Issue 2, 2018, Pages 141-150
dc.identifier07179227
dc.identifier00347388
dc.identifier10.4067/S0717-92272016000200008
dc.identifierhttps://repositorio.uchile.cl/handle/2250/166893
dc.description.abstractThe opinions about the relationship between antipsychotics and suicide are controversial due to differences on reported evidence about their specific action. One of the most discussed topics is the increase of depressive symptomatology and the impact of some secondary effects on suicidality, mainly akinesia, akathisia and tardive diskynesia. Another polemical topic is the paradoxical effect due to the decrease of positive symptoms when increasing insight. We performed a critical review of the available literature concerning to the use of antipsychotics in relation to suicide in the context of psychotic and affective disorders. When appraising psychotic disorders, there was no direct evidence to support a reduction in suicide rates when using first-generation antipsychotics, probably due to methodological issues and multifactoriality of the phenomenon. Nevertheless, second-generation antipsychotics could be protective against suicide risk, specifically clozapine, which is considered as
dc.languageen
dc.publisherSociedad de Neurologia Psiquiatria y Neurocirugia
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceRevista Chilena de Neuro-Psiquiatria
dc.subjectAntipsychotic
dc.subjectClozapine
dc.subjectSchizophrenia
dc.subjectSuicide
dc.titleAntipsychotics and suicide Antipsicóticos y suicidio
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución